MML Investors Services LLC Raises Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

MML Investors Services LLC raised its stake in Illumina, Inc. (NASDAQ:ILMN) by 10.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 25,888 shares of the life sciences company’s stock after buying an additional 2,515 shares during the quarter. MML Investors Services LLC’s holdings in Illumina were worth $3,459,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB bought a new position in shares of Illumina during the 3rd quarter worth approximately $772,000. Tidal Investments LLC increased its position in shares of Illumina by 38.0% during the third quarter. Tidal Investments LLC now owns 4,449 shares of the life sciences company’s stock worth $580,000 after purchasing an additional 1,226 shares in the last quarter. B. Riley Wealth Advisors Inc. increased its position in shares of Illumina by 66.8% during the third quarter. B. Riley Wealth Advisors Inc. now owns 11,973 shares of the life sciences company’s stock worth $1,582,000 after purchasing an additional 4,797 shares in the last quarter. Versant Capital Management Inc lifted its holdings in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Illumina by 6.1% in the 4th quarter. GAMMA Investing LLC now owns 3,096 shares of the life sciences company’s stock worth $414,000 after purchasing an additional 177 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Trading Down 0.3 %

Illumina stock opened at $77.35 on Friday. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The firm has a market cap of $12.24 billion, a PE ratio of -10.07, a P/E/G ratio of 1.60 and a beta of 1.38. The stock’s 50 day simple moving average is $82.02 and its two-hundred day simple moving average is $118.05. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ILMN. Morgan Stanley reduced their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. HSBC lowered shares of Illumina from a “buy” rating to a “hold” rating and set a $100.00 price objective for the company. in a research report on Friday, February 28th. Robert W. Baird dropped their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 5th. Piper Sandler raised their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Finally, Royal Bank of Canada lowered their price objective on shares of Illumina from $128.00 to $112.00 and set an “outperform” rating for the company in a research note on Tuesday, April 8th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $138.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.